Clinical Study Results
cover?
1. Study Name
Title of the Study: A Phase 3b, Open-label, Single-arm Study of the Efficacy
and Safety of Apremilast, in Subjects with Plaque Psoriasis
that is not Adequately Controlled by Topical Therapy
Brief Title: A Study of the Efficacy and Safety of Apremilast, in Subjects
With Plaque Psoriasis That is Not Adequately Controlled by
Topical Therapy
Protocol Number: CC-10004-PSOR-023 (20200062)
EU Trial Number: Not applicable
Other Identifiers: NCT03930186
Date of This 7 May 2021
Summary:
What does this summary cover?
This summary shows the main results from one clinical study. The results are only
for this study. Other studies may find different results. Researchers and health
authorities look at the results of many studies to decide which medicines work best
and are safest for participants.
Amgen has committed to make research results available to the public. This
summary has been provided as part of that commitment and should not be used for
any other purpose. It should not be considered to make a claim for any product or to
guide treatment decisions.
1